Search Results - "GURNEY, Mark"

Tumor Necrosis Factor (TNF) blocking agents are associated with lower risk for Alzheimer's disease in patients with rheumatoid arthritis and psoriasis by Zhou, Mengshi, Xu, Rong, Kaelber, David C, Gurney, Mark E

“…This large, retrospective case-control study of electronic health records from 56 million unique adult patients examined whether or not treatment with a Tumor…”
Get full text

COVID‐19 and dementia: Analyses of risk, disparity, and outcomes from electronic health records in the US by Wang, QuanQiu, Davis, Pamela B., Gurney, Mark E., Xu, Rong

“…Introduction At present, there is limited data on the risks, disparity, and outcomes for COVID‐19 in patients with dementia in the United States. Methods This…”
Get full text

The Use of Facebook Advertising to Recruit Healthy Elderly People for a Clinical Trial: Baseline Metrics by Cowie, Julie M, Gurney, Mark E

“…This report provides data on the use of social media advertising as a clinical trial recruitment strategy targeting healthy volunteers aged 60 years and older…”
Get full text

Genetic Association of Phosphodiesterases With Human Cognitive Performance by Gurney, Mark E

“…Recent, large-scale, genome-wide association studies (GWAS) provide a first view of the genetic fine structure of cognitive performance in healthy individuals…”
Get full text

Structural basis for the design of selective phosphodiesterase 4B inhibitors by Fox, David, Burgin, Alex B., Gurney, Mark E.

“…Phosphodiesterase-4B (PDE4B) regulates the pro-inflammatory Toll Receptor –Tumor Necrosis Factor α (TNFα) pathway in monocytes, macrophages and microglial…”
Get full text

PDE4 subtypes in cancer by Hsien Lai, Samuel, Zervoudakis, Guston, Chou, Jesse, Gurney, Mark E., Quesnelle, Kelly M.

“…Cyclic nucleotide phosphodiesterases (PDE) break down cyclic nucleotides such as cAMP and cGMP, reducing the signaling of these important intracellular second…”
Get full text

Inhibition of phosphodiesterase-4D in adults with fragile X syndrome: a randomized, placebo-controlled, phase 2 clinical trial by Berry-Kravis, Elizabeth M., Harnett, Mark D., Reines, Scott A., Reese, Melody A., Ethridge, Lauren E., Outterson, Abigail H., Michalak, Claire, Furman, Jeremiah, Gurney, Mark E.

“…The goal of this study was to determine whether a phosphodiesterase-4D (PDE4D) allosteric inhibitor (BPN14770) would improve cognitive function and behavioral…”
Get full text

Multiple Behavior Phenotypes of the Fragile-X Syndrome Mouse Model Respond to Chronic Inhibition of Phosphodiesterase-4D (PDE4D) by Gurney, Mark E., Cogram, Patricia, Deacon, Robert M, Rex, Christopher, Tranfaglia, Michael

“…Fragile-X syndrome (FXS) patients display intellectual disability and autism spectrum disorder due to silencing of the X-linked, fragile-X mental retardation-1…”
Get full text

Feeder Cells at the Interface of Natural Killer Cell Activation, Expansion and Gene Editing by Gurney, Mark, Kundu, Soumyadipta, Pandey, Shubham, O'Dwyer, Michael

“…Genome engineered natural killer (NK) cell therapies are emerging as a promising cancer immunotherapy platform with potential advantages and remaining…”
Get full text

CD38 knockout natural killer cells expressing an affinity optimized CD38 chimeric antigen receptor successfully target acute myeloid leukemia with reduced effector cell fratricide by Gurney, Mark, Stikvoort, Arwen, Nolan, Emma, Kirkham-McCarthy, Lucy, Khoruzhenko, Stanislav, Shivakumar, Rama, Zweegman, Sonja, Van de Donk, Niels W C J, Mutis, Tuna, Szegezdi, Eva, Sarkar, Subhashis, O'Dwyer, Michael

“…There is a strong biological rationale for the augmentation of allogeneic natural killer (NK) cell therapies with a chimeric antigen receptor (CAR) to enhance…”
Get full text

Therapeutic benefits of phosphodiesterase 4B inhibition after traumatic brain injury by Wilson, Nicole M, Gurney, Mark E, Dietrich, W Dalton, Atkins, Coleen M

“…Traumatic brain injury (TBI) initiates a deleterious inflammatory response that exacerbates pathology and worsens outcome. This inflammatory response is…”
Get full text

Effects of chronic inhibition of phosphodiesterase-4D on behavior and regional rates of cerebral protein synthesis in a mouse model of fragile X syndrome by Rosenheck, Michael, Sheeler, Carrie, Saré, Rachel Michelle, Gurney, Mark E., Smith, Carolyn Beebe

“…Fragile X Syndrome (FXS) is caused by silencing the FMR1 gene which results in intellectual disability, hyperactivity, sensory hypersensitivity, autistic-like…”
Get full text

Comparison of the Pharmacological Profiles of Selective PDE4B and PDE4D Inhibitors in the Central Nervous System by Zhang, Chong, Xu, Ying, Zhang, Han-Ting, Gurney, Mark E., O’Donnell, James M.

“…Inhibition of cyclic AMP (cAMP)-specific phosphodiesterase 4 (PDE4) has been proposed as a potential treatment for a series of neuropsychological conditions…”
Get full text

Coronary Artery-Bypass-Graft Surgery Increases the Plasma Concentration of Exosomes Carrying a Cargo of Cardiac MicroRNAs: An Example of Exosome Trafficking Out of the Human Heart with Potential for Cardiac Biomarker Discovery by Emanueli, Costanza, Shearn, Andrew I U, Laftah, Abas, Fiorentino, Francesca, Reeves, Barnaby C, Beltrami, Cristina, Mumford, Andrew, Clayton, Aled, Gurney, Mark, Shantikumar, Saran, Angelini, Gianni D

“…Exosome nanoparticles carry a composite cargo, including microRNAs (miRs). Cultured cardiovascular cells release miR-containing exosomes. The exosomal…”
Get full text

Design of phosphodiesterase 4D (PDE4D) allosteric modulators for enhancing cognition with improved safety by Burgin, Alex B, Gurney, Mark E, Magnusson, Olafur T, Singh, Jasbir, Witte, Pam, Staker, Bart L, Bjornsson, Jon M, Thorsteinsdottir, Margret, Hrafnsdottir, Sigrun, Hagen, Timothy, Kiselyov, Alex S, Stewart, Lance J

“…Finding safe inhibitors of phosphodiesterase 4, the enzyme that breaks down cAMP, has been a longstanding goal in pharmaceutical development. Burgin et al …”
Get full text

Memory enhancing effects of BPN14770, an allosteric inhibitor of phosphodiesterase-4D, in wild-type and humanized mice by Zhang, Chong, Xu, Ying, Chowdhary, Anirudh, Fox, 3rd, David, Gurney, Mark E, Zhang, Han-Ting, Auerbach, Benjamin D, Salvi, Richard J, Yang, Mingxin, Li, Gaowen, O'Donnell, James M

“…Inhibitors of phosphodiesterase-4 (PDE4) have beneficial effects on memory in preclinical and clinical studies. Development of these drugs has stalled due to…”
Get full text

Membrane Radiolabelling of Exosomes for Comparative Biodistribution Analysis in Immunocompetent and Immunodeficient Mice - A Novel and Universal Approach by Faruqu, Farid N, Wang, Julie Tzu-Wen, Xu, Lizhou, McNickle, Luke, Chong, Eden Ming-Yiu, Walters, Adam, Gurney, Mark, Clayton, Aled, Smyth, Lesley A, Hider, Robert, Sosabowski, Jane, Al-Jamal, Khuloud T

“…Extracellular vesicles, in particular exosomes, have recently gained interest as novel drug delivery vectors due to their biological origin and inherent…”
Get full text

Protection from Amyloid β Peptide-Induced Memory, Biochemical, and Morphological Deficits by a Phosphodiesterase-4D Allosteric Inhibitor by Cui, Su-Ying, Yang, Ming-Xin, Zhang, Yong-He, Zheng, Victor, Zhang, Han-Ting, Gurney, Mark E, Xu, Ying, O'Donnell, James M

“…Recent imaging studies of amyloid and tau in cognitively normal elderly subjects imply that Alzheimer's pathology can be tolerated by the brain to some extent…”
Get more information

Phosphodiesterase-4 (PDE4) Molecular Pharmacology and Alzheimer’s Disease by Gurney, Mark E., D’Amato, Emily C., Burgin, Alex B.

“…Between 20% and 25% of patients diagnosed with Alzheimer’s disease (AD) do not have amyloid burden as assessed by positron emission tomography imaging. Thus,…”
Get full text

Dominant immunosuppression of dendritic cell function by prostate-cancer-derived exosomes by Salimu, Josephine, Webber, Jason, Gurney, Mark, Al-Taei, Saly, Clayton, Aled, Tabi, Zsuzsanna

“…Exosomes are a distinct population of extracellular vesicles of endocytic origin with a protein repertoire similar to the parent cell. Although tumour-derived…”
Get full text